Shopping Cart

No products in the cart.

Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Androgen Deprivation Therapy-Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients.

Androgen deprivation therapy (ADT) increases the risk of adverse cardiovascular events in patients with prostate cancer. ADT can induce body composition change; however, the association between body composition change and cardiovascular outcomes remains unclear. This study aimed to determine the...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAndrogen Deprivation Therapy-Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients.

Myogenic nano-adjuvant for orthopedic-related sarcopenia via mitochondrial homeostasis modulation in macrophage-myosatellite metabolic crosstalk.

The decline in skeletal muscle mass and muscle strength linked to aging, also known as sarcopenia, is strongly associated with disability, traumatic injury, and metabolic disease in patients. Meanwhile, sarcopenia increases the risk of adverse orthopedic perioperative complications including implant...

๐Ÿ—“๏ธ 2025-05-28
๐Ÿ“ฐ Publication: Journal Of Nanobiotechnology
Read MoreMyogenic nano-adjuvant for orthopedic-related sarcopenia via mitochondrial homeostasis modulation in macrophage-myosatellite metabolic crosstalk.

Normative data for age-specific skeletal muscle area based on computed tomography in Korean population.

Sarcopenia, a progressive loss of muscle mass and function, increases health risks in older adults, especially in rapidly ageing populations like Korea. Computed tomography (CT) imaging at the third lumbar vertebra (L3) level is a gold standard for assessing skeletal...

๐Ÿ—“๏ธ 2025-05-03
๐Ÿ“ฐ Publication: Age And Ageing
Read MoreNormative data for age-specific skeletal muscle area based on computed tomography in Korean population.

Iron Metabolism and Muscle Aging: Where Ferritinophagy Meets Mitochondrial Quality Control.

In older adults with reduced physical performance, an increase in the labile iron pool within skeletal muscle is observed. This accumulation is associated with an altered expression of mitochondrial quality control (MQC) markers and increased mitochondrial DNA damage, supporting the...

๐Ÿ—“๏ธ 2025-05-03
Read MoreIron Metabolism and Muscle Aging: Where Ferritinophagy Meets Mitochondrial Quality Control.

Potential framework of the Global Leadership Initiative in Sarcopenia (GLIS) criteria based on muscle mass and/or strength for predicting survival in cancer patients: A nationwide multicenter cohort study.

The Global Leadership Initiative on Sarcopenia (GLIS) was proposed recently by creating a widely recognized conceptual definition of sarcopenia, however, the diagnostic framework of GLIS in cancer patients remains unclear. This study aims to evaluate the potential framework of GLIS...

๐Ÿ—“๏ธ 2025-04-24
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MorePotential framework of the Global Leadership Initiative in Sarcopenia (GLIS) criteria based on muscle mass and/or strength for predicting survival in cancer patients: A nationwide multicenter cohort study.

MG53 deficiency mediated skeletal muscle dysfunction in chronic obstructive pulmonary disease via impairing mitochondrial fission.

Myokine dysregulation and mitochondrial dysfunction are implicated in the pathogenesis of sarcopenia in chronic obstructive pulmonary disease. The objective of this study is to explore the role of myokines and mitochondrial dysfunction in sarcopenia in chronic obstructive pulmonary disease. We...

๐Ÿ—“๏ธ 2025-05-03
๐Ÿ“ฐ Publication: Redox Biology
Read MoreMG53 deficiency mediated skeletal muscle dysfunction in chronic obstructive pulmonary disease via impairing mitochondrial fission.

The potential of TAOK1 as a new therapeutic target for the treatment of cancer cachexia-associated muscle atrophy.

Cancer cachexia, a multifactorial metabolic syndrome impacts 50-80% cancer patients, is mainly characterized by skeletal muscle atrophy. In this study, we demonstrated that the thousand-and-one amino acid kinase 1 (TAOK1) was activated in both C2C12 myotubes treated with simulated cancer...

๐Ÿ—“๏ธ 2025-05-06
๐Ÿ“ฐ Publication: Pharmacological Research
Read MoreThe potential of TAOK1 as a new therapeutic target for the treatment of cancer cachexia-associated muscle atrophy.

Prevalence of sarcopenia in middle-aged and older adults with cognitive impairment: a meta-analysis.

Cognitive impairment, dementia and sarcopenia significantly reduce the quality of life in middle-aged and older adults by impairing daily functioning, making cognitive decline a major concern for healthcare professionals. To estimate the prevalence of sarcopenia and probable sarcopenia in middle-aged...

๐Ÿ—“๏ธ 2025-05-03
๐Ÿ“ฐ Publication: Age And Ageing
Read MorePrevalence of sarcopenia in middle-aged and older adults with cognitive impairment: a meta-analysis.

Comment on "Reduced temporal muscle thickness predicts shorter survival in patients undergoing chronic subdural haematoma drainage" by Korhonen etย al.-The authors' reply.

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreComment on "Reduced temporal muscle thickness predicts shorter survival in patients undergoing chronic subdural haematoma drainage" by Korhonen etย al.-The authors' reply.

The extract of chrysanthemum flos mitigates post-stroke sarcopenia by inhibiting PANoptosis and restoring muscle homeostasis.

Sarcopenia and muscle weakness are prevalent complications of ischemic stroke (IS), with limited pharmacological options. This study identifies high-dose extracts of Chrysanthemum Flos (ECF) as a potential therapy for post-stroke muscle dysfunction by targeting PANoptosis-a pro-inflammatory programmed cell death pathway....

๐Ÿ—“๏ธ 2025-04-18
๐Ÿ“ฐ Publication: Phytomedicine
Read MoreThe extract of chrysanthemum flos mitigates post-stroke sarcopenia by inhibiting PANoptosis and restoring muscle homeostasis.

Integrated Multiomics Analyses of the Molecular Landscape of Sarcopenia in Alcohol-Related Liver Disease.

Skeletal muscle is a major target for ethanol-induced perturbations, leading to sarcopenia in alcohol-related liver disease (ALD). The complex interactions and pathways involved in adaptive and maladaptive responses to ethanol in skeletal muscle are not well understood. Unlike hypothesis-driven experiments,...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreIntegrated Multiomics Analyses of the Molecular Landscape of Sarcopenia in Alcohol-Related Liver Disease.

Myosteatosis as a New Risk Factor of Surgical Complications in Kidney Transplant Recipients: A Retrospective Study.

Computed tomography (CT) scan-defined myosteatosis is a common feature in ESKD patients receiving kidney transplantation (KT) and is associated with mortality after KT. We aimed to explore the impact of myosteatosis and other CT scan based morphometric data on the...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMyosteatosis as a New Risk Factor of Surgical Complications in Kidney Transplant Recipients: A Retrospective Study.

A 10-Year Longitudinal Study of Muscle Morphology and Performance in Masters Sprinters.

Both longitudinal and cross-sectional studies have demonstrated that muscle mass, strength and power are lost with ageing. Although longitudinal studies have shown changes in muscle morphology and function in sedentary, healthy active and endurance-trained older people, less is known about...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreA 10-Year Longitudinal Study of Muscle Morphology and Performance in Masters Sprinters.

Myo-Guide: A Machine Learning-Based Web Application for Neuromuscular Disease Diagnosis With MRI.

Neuromuscular diseases (NMDs) are rare disorders characterized by progressive muscle fibre loss, leading to replacement by fibrotic and fatty tissue, muscle weakness and disability. Early diagnosis is critical for therapeutic decisions, care planning and genetic counselling. Muscle magnetic resonance imaging...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMyo-Guide: A Machine Learning-Based Web Application for Neuromuscular Disease Diagnosis With MRI.

The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.

Sarcopenia is associated with the loss of skeletal muscle function and mass. Nicotinamide precursors, such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), have received attention for their potential to improve NAD levels and mitigate age-related sarcopenia in preliminary models,...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThe Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.

Modulating phosphatase DUSP22 with BML-260 ameliorates skeletal muscle wasting via Akt independent JNK-FOXO3a repression.

Skeletal muscle wasting results from numerous conditions, such as sarcopenia, glucocorticoid therapy or intensive care. It prevents independent living in the elderly, predisposes to secondary diseases, and ultimately reduces lifespan. There is no approved drug therapy and the major causative...

๐Ÿ—“๏ธ 2025-04-22
๐Ÿ“ฐ Publication: Embo Molecular Medicine
Read MoreModulating phosphatase DUSP22 with BML-260 ameliorates skeletal muscle wasting via Akt independent JNK-FOXO3a repression.

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 โ€“ Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 โ€“ The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP.ย Why cachexia kills: examining the causality of poor outcomes in wasting conditions.ย J Cachexia Sarcopenia Muscle 2013; 4: 89โ€“94.

Evans WJ, Morley JE, Argilรฉs J, Bales C, Baracos V, Guttridge D, et al.ย Cachexia: a new definition.ย Clin Nutr 2008; 27: 793โ€“799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al.ย Muscle wasting disease: a proposal for a new disease classification.ย J Cachexia Sarcopenia Muscle 2014; 5: 1โ€“3.

Argiles JM, Busquets S, Stemmler B, Lรณpez-Soriano FJ.ย Cachexia and sarcopenia: mechanisms and potential targets for intervention.ย Current Opinion in Pharmacology 2015; 22: 100โ€“106.

Bowen TS, Schuler G, Adams V.ย Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.ย J Cachexia Sarcopenia Muscle 2015; 6: 197โ€“207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!